Lassa Fever

Lassa fever is a severe viral hemorrhagic illness caused by theLassa virus (LASV), an arenavirus endemic to West Africa, particularly in countries like Nigeria and Sierra Leone.^[1] The virus is primarily transmitted to humans through contact with food or household items contaminated with the urine or feces of infected multimammate rats (Mastomys natalensis). Person-to-person transmission can also occur through direct contact with the blood, urine, feces, or other bodily secretions of an infected individual.

Biological Basis

The Lassa virus infects cells by binding to specific host receptors. The primary cellular receptor for LASV is alpha-dystroglycan.^[2] The LARGE1 gene encodes a glycosyltransferase enzyme that modifies alpha-dystroglycan, and the level of LARGE1 expression is crucial for Lassa virus binding and infectivity.^[2] Research indicates that human genetic variation significantly influences both susceptibility to Lassa virusinfection and the severity of disease outcome.^[1] For instance, studies have identified genome-wide significant variant associations with fatal outcomes near the GRM7 and LIF genes.^[1] Furthermore, a specific haplotype overlapping the LARGE1gene, which bears signatures of positive selection, has been associated with a decreased risk of Lassa fever.^[1] The human leukocyte antigen (HLA) region, known for its role in immune response, is also being investigated for its association with Lassa fever phenotypes.^[1]

Clinical Relevance

While many individuals infected with Lassa virus may experience no symptoms or only mild illness, others develop severe hemorrhagic fever.^[1] The estimated fatality rate among diagnosed cases can be as high as 29.7%.^[1]Common symptoms include fever, malaise, headache, sore throat, cough, and vomiting, with younger patients often presenting with vomiting and cough.^[1] Severe manifestations can include hemorrhage, neurological complications, and acute sensorineural deafness.^[3]Diagnosing Lassa fever is challenging, as there are currently no US Food and Drug Administration-approved diagnostics, and methods often rely on viral culture or immunoassays which can have low sensitivity.^[4]

Social Importance

Lassa fever represents a significant public health challenge in West Africa due to its endemic nature, potential for outbreaks, and high fatality rate in severe cases.^[1]The disease places a considerable burden on healthcare systems and affected communities. Understanding the host genetic factors that contribute to resistance or susceptibility is crucial for elucidating the biological mechanisms underlying the disease and could inform the development of improved diagnostic tools, treatments, and prevention strategies.^[1]The identification of genetic variants associated with disease outcome highlights the potential for personalized risk assessment and targeted interventions.

Methodological and Statistical Constraints

Genetic association studies are often constrained by sample size and the ability to replicate findings across diverse cohorts. The relatively small sample sizes, such as an HLA sequencing cohort of 297 individuals, inherently limit statistical power, increasing the risk of false negatives and making it challenging to detect subtle genetic associations.^[1] Furthermore, the observed large effect sizes for some variants might be subject to “winner’s curse,” a phenomenon where reported effect sizes are systematically inflated when only statistically significant or near-significant findings are published, necessitating larger replication studies for validation.^[1] This limitation was underscored by a hypothesis regarding the LARGE1 locus, which showed promising support in an earlier cohort but failed to replicate in a subsequent one, potentially due to power limitations or underlying temporal differences between the cohorts.^[1] The reliance on imputing causal variants from genotyping arrays, particularly in populations with unique genetic diversity, introduces further constraints. Accurate imputation requires comprehensive genotyping arrays and large whole-genome sequencing reference panels that adequately represent the population of interest, both of which are often deficient for African populations.^[1] Reduced imputation accuracy in such contexts can significantly diminish the power of genome-wide association studies, making the identification of true genetic signals more challenging.^[1]Such methodological factors highlight the ongoing need for improved genetic data resources and larger, well-powered cohorts to enhance the detection and confirmation of genetic associations with Lassa fever.^[1]

Generalizability and Ancestry-Specific Data Gaps

The genetic landscape of African populations is characterized by high diversity and lower levels of linkage disequilibrium, posing specific challenges for genetic association studies, especially those focused on infectious diseases prevalent in Africa.^[1] This inherent diversity, coupled with the historical under-representation of African ancestry individuals in global genetic reference panels, can lead to reduced imputation accuracy for ungenotyped variants.^[1] Consequently, findings from such studies may have limited generalizability beyond the specific cohorts examined, and the absence of African ancestry data in resources like the Genotype-Tissue Expression dataset can hinder the functional interpretation of identified regulatory variants.^[1]The findings from specific cohorts in Nigeria and Sierra Leone, while crucial, may not be fully generalizable across the broader African continent. Significant genetic divergence between different Lassa virus lineages, as well as varying host genetic backgrounds and environmental exposures across regions, mean that genetic associations identified in one area might not directly translate or hold the same effect size in another.^[1]This emphasizes the importance of expanding genetic characterization efforts to include more diverse African populations to capture the full spectrum of genetic variation influencing Lassa fever susceptibility and outcome.^[1]

Phenotypic Nuance and Environmental Confounding

Accurately defining cases and controls for Lassa fever studies presents considerable challenges, particularly when utilizing population controls with unknown prior exposure to LASV.^[1]While serology is employed to characterize prior exposure, its interpretation is complex: asymptomatic infections may not lead to sustained seropositivity (resulting in false negatives), or positive serology could indicate past, undocumented Lassa fever rather than asymptomatic illness.^[1] In such scenarios, controls might inadvertently carry susceptibility alleles, thereby reducing the statistical power to detect genuine associations.^[1]The absence of detailed disease histories and more extensive serological characterization further complicates the distinction between individuals with previous Lassa fever and those with asymptomatic infection.^[1]Beyond host genetics, a multitude of environmental and biological confounders can significantly influence disease outcomes and complicate genetic association studies. Factors such as the high genetic diversity of the Lassa virus (up to 27% nucleotide diversity) and the distinct viral lineages found in different geographic regions could lead to varied mechanisms of host interaction and disease progression.^[1]Furthermore, previous infections with other endemic pathogens, co-infections, patient comorbidities, and other health factors can act as drivers of observed symptoms and disease outcomes, potentially masking or modulating genetic effects.^[1] The omission of key covariates, such as age, from primary analyses due to missing data for a substantial proportion of participants, can also impact statistical power and the robustness of reported findings.^[1]

Variants

Genetic variations play a crucial role in determining an individual’s susceptibility to Lassa fever and the severity of its outcome. Several specific single nucleotide polymorphisms (SNPs) and their associated genes have been identified as having significant implications for Lassa virus infection, influencing aspects from viral entry to immune response and disease progression. These variants, often with low allele frequencies but potentially large biological effects, offer insights into the complex host-pathogen interactions that define Lassa fever.

The rs9870087 variant, an intronic polymorphism within the GRM7gene, is strongly associated with fatal outcomes of Lassa fever, particularly observed in the Nigerian cohort, with an odds ratio of 15.4.^[1] The GRM7gene encodes a metabotropic glutamate receptor, a protein active in the central nervous system, and while its direct role in viral infection is being explored, otherGRM family members have been linked to viral entry mechanisms. Furthermore, GRM7is essential for the function of inner-ear hair cells, and hearing loss is a recognized symptom of Lassa fever, suggesting that this variant might influence disease severity through neuroimmune signaling or by affecting pathways related to this common complication.^[1] Another significant variant, rs114992845 , located within an intron of the CNTNAP2gene, is a key locus associated with Lassa fever susceptibility.CNTNAP2 (Contactin Associated Protein 2) is a member of the neurexin family, many of whose proteins bind to alpha-dystroglycan, a known cellular receptor for Lassa virus entry into host cells.^[1] This variant showed the most significant association in a meta-analysis for susceptibility, with odds ratios of 9.19 in Nigeria and 4.77 in Sierra Leone.^[1] The involvement of CNTNAP2 in viral entry and the observation that loss-of-function mutations in this gene are linked to recurrent infections underscore its potential role in modulating the body’s defense against Lassa virus.

The variant rs73404538 , situated downstream of the LIFgene, is significantly associated with fatal outcomes in Lassa fever, showing protective effects in both Nigerian and Sierra Leonean cohorts.^[1] LIF(Leukemia Inhibitory Factor) encodes an interleukin 6 family cytokine, a crucial mediator of immune and inflammatory responses, known for its protective role against lung injury in other viral infections and its upregulation in acute infection stages.^[1] The variant’s position suggests it may influence the expression of LIF, potentially altering the host’s immune response to Lassa virus. Additionally, rs73404538 shows a nominal association with Lassa fever susceptibility, suggesting it may contribute to both the likelihood of contracting the disease and its clinical severity. The nearbyHORMAD2 gene’s function is unrelated to LIF but it is located in the vicinity.

Two other variants show trends toward significance in Lassa fever susceptibility. Thers73397758 variant, located downstream of CASC17 (a long non-coding RNA) and upstream of KCNJ2, exhibits an association with susceptibility in the Sierra Leone cohort.^[1] Long non-coding RNAs like CASC17 can regulate gene expression and cellular pathways, potentially impacting the immune response or viral replication. While CALM2P1is a pseudogene in the region, its direct role with this specific variant in Lassa fever is not explicitly defined. Similarly,rs143130878 , found downstream of CCT6B, also trends towards significance for Lassa fever susceptibility in the Sierra Leone cohort.^[1] CCT6Bis a subunit of the molecular chaperone complex TRiC, which is known to regulate the replication of arenaviruses, including Lassa virus, highlighting a potential mechanism through which this variant might influence disease outcome by affecting viral multiplication.^[1] The TMEM132E gene is a neighboring gene, but the primary contextual relevance of rs143130878 lies with CCT6B’s direct role in viral processes.

Key Variants

RS ID	Gene	Related Traits
rs9870087	GRM7	lassa fever
rs73397758	CALM2P1 - CASC17	lassa fever
rs143130878	TMEM132E - CCT6B	lassa fever
rs114992845	CNTNAP2	lassa fever
rs73404538	HORMAD2 - LIF-AS1	lassa fever

Defining Lassa Fever: Etiology and Clinical Profile

Lassa fever is precisely defined as an acute viral hemorrhagic illness resulting from infection with the Lassa virus (LASV).^[1]This zoonotic disease is primarily transmitted to humans through direct or indirect contact with the urine, feces, or saliva of infected multimammate rats (Mastomys natalensis), which serve as the principal reservoir host in endemic regions.^[1] While the aerosol-based route of exposure is a recognized concern, the illness manifests across a broad clinical spectrum, ranging from asymptomatic cases to severe, life-threatening outcomes characterized by rapid progression.^[1] Initial symptoms commonly include fever, vomiting, cough, and sore throat, which can escalate to critical conditions such as respiratory distress, mucosal bleeding, shock, and multiorgan failure.^[1]

Diagnostic Criteria and Measurement Approaches

The operational definition of a suspected Lassa fever case typically integrates specific clinical diagnostic criteria, particularly in areas with limited advanced diagnostic capabilities.^[1] These criteria include a fever exceeding 38°C for less than three weeks, an absence of signs of local inflammation, and a lack of clinical response to anti-malarial treatments, often complemented by other major and minor clinical indicators.^[1]Confirmatory diagnostic measurement approaches rely on laboratory testing, encompassing molecular diagnostic testing for the presence of LASV RNA and serological assays like ELISA for detecting LASV antigens or immunoglobulin M (IgM) antibodies, which signify acute infection.^[1]Additionally, the detection of immunoglobulin G (IgG) seropositivity is a valuable epidemiological measure, with its association with older age suggesting continuous lifetime exposure to the virus.^[1]

Classification Systems and Key Terminology

Lassa fever’s classification as a significant global health threat stems from its high lethality and potential for wide dissemination, leading the World Health Organization to categorize LASV as a risk group 4 pathogen and a biosafety level 4 (BSL-4) agent.^[1]The severity of the disease is frequently quantified by its Case Fatality Rate (CFR), which can reach 29.7% in laboratory-confirmed patients and exceed 50% in fetuses, with notable geographical variations, such as reported CFRs of 35.3% in Nigeria and 64.8% in Sierra Leone within specific study cohorts.^[1] Key terminology related to the virus includes its genetic diversity, with distinct clades such as clade II or III typically found in Nigeria and clade IV in Sierra Leone, reflecting the virus’s phylogeographic distribution.^[1] Furthermore, research into host genetic susceptibility utilizes terms like Human Leukocyte Antigen (HLA) and specific genetic variants or haplotypes, such as the LARGE-LRH within the LARGE1 gene, which is understood to be a critical factor for LASV entry into host cells.^[1]

Initial Clinical Manifestations and Disease Progression

Lassa fever typically presents with a range of symptoms, often beginning with an elevated body temperature exceeding 38°C for less than three weeks, in the absence of signs of local inflammation and a lack of clinical response to anti-malarial treatments.^[1] Common symptoms observed include vomiting and cough, which are more frequently reported in younger patients.^[1] The case fatality rate (CFR) can vary significantly by region, with estimates of 35.3% in Nigeria and 64.8% in Sierra Leone.^[1]

Heterogeneity in Clinical Presentation and Outcomes

The clinical presentation and outcomes of Lassa fever exhibit considerable variability across individuals, influenced by factors such as age, sex, and host genetics. Younger patients are statistically more prone to presenting with vomiting and cough . Next-generation sequencing has also been leveraged to identify additional cases that might be missed by conventional diagnostics, enhancing the breadth of case detection . Specifically, theLARGE-LRHhaplotype has shown an association with Lassa fever susceptibility in endemic populations.^[1] Further genetic insights include variants in GRM7, an intronic region of which is significantly associated with Lassa fever outcome in some cohorts; this gene may influence viral entry or immune activation and is also implicated in hearing maintenance, a known symptom of Lassa fever. TheLIFgene, encoding an interleukin-6 family cytokine, has a downstream variant associated with fatal outcomes, suggesting its role in modulating the immune response to infection and potentially increasing the likelihood of clinically detected disease. Additionally, thers114992845 variant within an intron of CNTNAP2 has emerged as a significant factor in meta-analyses; CNTNAP2 is part of a family whose members interact with α-dystroglycan, and its loss-of-function mutations are linked to recurrent infections. While no Human Leukocyte Antigen (HLA) alleles reached genome-wide significance, DRB1*15:03showed the strongest evidence of association, indicating the complex and polygenic nature of genetic susceptibility to this infectious disease.^[1]

Environmental Exposure and Geographic Determinants

The fundamental cause of Lassa fever is infection with the Lassa virus (LASV), an Old World arenavirus. Human infection is acquired through direct contact with infected rodents, particularly the multimammate rat (Mastomys natalensis), or their excretions, or through person-to-person transmission, especially in healthcare settings without adequate infection control. The disease is geographically restricted to West African countries, primarily Sierra Leone, Liberia, Guinea, and Nigeria, where the rodent reservoir is endemic and human populations are regularly exposed.^[1]The prevalence of Lassa fever is directly tied to living conditions and practices that facilitate contact between humans and theMastomys rodent, such as inadequate sanitation, food storage, and housing that allows rodent ingress. Furthermore, the genetic diversity observed among Lassa virus strains suggests an evolving pathogen that interacts with its environment and host populations.^[5]Therefore, environmental factors dictating exposure to the virus in endemic regions are critical prerequisites for the disease.

Gene-Environment Interactions and Disease Modifiers

The progression and severity of Lassa fever are not solely determined by viral exposure but also by the intricate interactions between the host’s genetic makeup and environmental triggers. For example, host genetic variants influencingLARGE1 expression or the LIF pathway can significantly modify the outcome of LASVexposure, dictating whether an individual remains asymptomatic, develops mild disease, or progresses to severe, often fatal, illness.^[1]This highlights how genetic predisposition can alter an individual’s immune response and cellular permissiveness to the virus, shifting the clinical trajectory following environmental exposure.

Age also acts as a significant modifier of disease presentation and outcome. Research indicates that younger patients with Lassa fever are more prone to presenting with symptoms such as vomiting and cough. Conversely, there is an observable trend towards a higher probability of fatal outcomes in older individuals, suggesting age-related physiological changes and immune senescence may exacerbate disease severity upon infection.^[1]These observations underscore that the multifaceted nature of Lassa fever arises from a dynamic interplay between viral presence in specific environments, host genetic vulnerabilities, and demographic factors like age.

Lassa Virus: Transmission and Cellular Infection

Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus (LASV), an RNA virus belonging to the Arenaviridae family. The primary natural reservoir for LASV is the multimammate rat,Mastomys natalensis, a rodent species commonly found in and around human dwellings in rural villages in West Africa.^[1]Human infection typically occurs through contact with food or household items contaminated with rodent urine or feces, leading to aerosolization and inhalation of viral particles.^[1] While antibody surveys indicate widespread exposure to LASV, ranging from 8% to 52% of residents in endemic regions, leading to an estimated 100,000 to 300,000 infections annually, only a fraction of these cases, hundreds to thousands, are clinically diagnosed each year.^[6] This suggests that most infections are either asymptomatic or result in mild, undocumented illness.^[1] Person-to-person transmission is also possible, although it is primarily observed in nosocomial settings.^[1]At a cellular level, Lassa virus initiates infection by binding to its primary cellular receptor,alpha-dystroglycan, a highly glycosylated cell surface protein.^[7] The glycosylation of alpha-dystroglycan is a critical step for virus binding and subsequent entry, a process significantly influenced by the LARGE1 gene.^[2] LARGE1 encodes a glycosyltransferase enzyme responsible for modifying alpha-dystroglycan, and the level of LARGE1 expression directly impacts LASV infectivity in vitro.^[2]

Host Genetic Factors and Immune Response

The variability in Lassa fever outcomes, from asymptomatic infection to severe disease and fatality, is influenced by human genetic variation.^[1]Research indicates that natural selection may have played a role in shaping host genetic resistance to Lassa fever, potentially increasing the prevalence of protective alleles in endemic populations.^[8] For instance, a genomic locus overlapping the LARGE1 gene has shown evidence of positive selection.^[8] Variants within this region are hypothesized to impact LARGE1 gene expression levels, thereby influencing the glycosylation of alpha-dystroglycanand ultimately reducing the risk of severe Lassa fever.^[1]Such protective variants, if common, could be detectable even in genetic association studies of moderate sample size.^[9]Several genes involved in immune regulation and cellular function have been implicated in Lassa fever outcomes. A variant located downstream of theLIF gene (rs73404538 ) has been significantly associated with fatal outcomes from Lassa fever and may also increase the probability of clinically detectable infection.^[1] LIFencodes a cytokine from the interleukin 6 family, known for its pleiotropic effects, including protection against lung injury and its upregulation during acute viral and bacterial infections.^[1]Altered regulation of this cytokine due to host genetic variation could critically impact disease severity. Furthermore, an intronic variant within theGRM7gene has been associated with Lassa fever.^[1] GRM7 may contribute to immune activation, suggesting its role in the host’s inflammatory response to the virus.^[1]While specific single nucleotide polymorphisms (SNPs) within the Human Leukocyte Antigen (HLA) region did not reach genome-wide significance in some studies, HLA genes are well-known for their critical role in presenting antigens to T cells and are broadly associated with various infectious disease phenotypes.^[10]

Pathophysiology and Clinical Outcomes

Despite the high prevalence of Lassa virus exposure, only a minority of infected individuals develop clinically severe Lassa fever, which can lead to death.^[1]The clinical diagnosis of Lassa fever typically involves symptoms such as fever above 38°C lasting less than three weeks, an absence of signs of local inflammation, and no clinical response to antimalarial treatments, alongside other major and minor signs.^[1] Certain demographic factors, such as old age and pregnancy, are consistently associated with a poorer prognosis and increased risk of fatal outcome.^[11] Young patients, however, may present more frequently with symptoms like vomiting and cough.^[1]Lassa fever can manifest with a range of systemic consequences, affecting multiple tissues and organs. A particularly notable symptom of Lassa fever is acute sensorineural deafness.^[1] This specific neurological complication may be biologically linked to the GRM7 gene, which plays an important role in maintaining the function of inner-ear hair cells.^[1] The pleiotropic nature of cytokines like those encoded by LIF suggests broader systemic involvement.^[1] For instance, LIF’s established role in protecting against lung injury in other viral infections hints at potential respiratory pathophysiology in severe Lassa fever cases, though specific details of its direct impact on Lassa fever-related organ damage are still under investigation.^[1]

Viral Entry and Host Receptor Dynamics

Lassa virus (LASV) initiates infection by engaging specific host cellular receptors, primarily alpha-dystroglycan.^{[2], [7]} A critical host protein in this process is LARGE1, which encodes a glycosyltransferase responsible for the necessary post-translational modification, or glycosylation, of alpha-dystroglycan.^[2] This specific glycosylation is essential for LASV binding to the cell surface, and variations in the expression levels of LARGE1 directly influence the efficiency of LASV infectivity in laboratory settings.^[2] Host genetic variants within the LARGE1 gene region, including a specific haplotype known as LARGE-LRH, are associated with Lassa fever susceptibility and may impactLARGE1 expression levels, thereby modulating the initial viral entry pathway.^[1]

Immune Signaling and Inflammatory Responses

The host’s immune response to LASV is a complex process influenced by intrinsic signaling pathways. A variant located downstream of the LIFgene, which encodes an interleukin 6 family cytokine, is significantly associated with fatal outcomes in Lassa fever.^[1] LIFis a pleiotropic cytokine known to play roles in immune regulation, exhibiting protective effects against lung injury in other viral infections and being upregulated during acute infectious states.^[1] Therefore, host genetic variations that alter the regulation or function of LIFcould critically impact the signaling cascades that govern the severity of the inflammatory response and overall disease progression.^[1] Furthermore, the GRM7gene, an intronic variant within which is also associated with fatal Lassa fever, may contribute to immune activation, suggesting its involvement in the complex signaling networks that modulate the host’s defense mechanisms againstLASV.^[1]

Genetic Regulation of Disease Phenotypes

Genetic regulatory mechanisms play a fundamental role in shaping the individual response to Lassa fever, influencing both susceptibility and disease severity. Variants identified in regions associated with Lassa fever outcome, such as those withinGRM7 and downstream of LIF, can affect gene regulation, potentially altering the transcription and expression of these critical proteins.^[1] Specific variants within the LARGE1 region have demonstrated significant allelic skew in reporter assays, suggesting their capacity to regulate gene expression levels.^[1]Such regulatory changes can lead to altered availability of viral receptors, modified cytokine signaling, or other cellular dysfunctions, directly contributing to the diverse clinical manifestations and outcomes observed in Lassa fever.^[1]

Systems-Level Host-Pathogen Interactions

Lassa fever pathogenesis is characterized by an intricate systems-level integration of host genetic factors and viral activities. The identified genetic associations with genes likeLIF, GRM7, and LARGE1underscore how variations in seemingly distinct biological pathways—from initial viral entry mechanisms to subsequent immune modulations—interact and converge to define the overall disease phenotype.^[1] For instance, alterations in LARGE1-mediated viral entry can directly impact the viral burden, which, in turn, can trigger specific LIF-mediated immune and inflammatory responses, creating a complex network of interactions. These interconnected pathways, perturbed by host genetic variants, lead to emergent properties of the infection, dictating critical aspects such as disease severity, progression, and fatal outcomes.^[1]

Clinical Relevance of Genetic Factors in Lassa Fever

Lassa fever, caused by Lassa virus (LASV), presents with highly variable clinical outcomes, ranging from asymptomatic infection to severe hemorrhagic illness and multiorgan failure, with case fatality rates as high as 29.7% in confirmed cases and over 50% in fetuses.^[1]Understanding the underlying factors contributing to this heterogeneity is crucial for improving patient care, informing public health strategies, and guiding therapeutic development. Recent genome-wide association studies (GWAS) have begun to elucidate the human genetic architecture influencing Lassa fever susceptibility and fatal outcomes.^[1]

Genetic Determinants of Lassa Fever Susceptibility and Outcome

Genetic variants play a significant role in determining an individual’s risk of developing severe Lassa fever. A genome-wide association study conducted in Nigerian and Sierra Leonean cohorts identified specific variants associated with fatal outcomes. Notably, an intronic variant within theGRM7 gene and a variant downstream of the LIFgene were found to be significantly associated with Lassa fever fatality.^[1]These findings suggest that variations in these genes can serve as prognostic markers, helping to predict disease progression and overall outcome in infected individuals. Furthermore, the variantrs73404538 , located downstream of LIF, was associated with increased lethality and also showed nominal significance for increasing the probability of contracting clinically detected Lassa fever.^[1]Beyond predicting severe disease, human genetic variation may also influence susceptibility. The research identified a specific haplotype overlappingLARGE1, a gene encoding a required LASV entry factor, which was associated with a decreased risk of Lassa fever in the Nigerian cohort.^[1] This LARGE1haplotype, which bears signatures of positive selection, could potentially be used in risk stratification to identify individuals with a lower genetic predisposition to infection, guiding prevention strategies and potentially informing targeted interventions in endemic areas.^[1] While HLAalleles were investigated, no significant associations with Lassa fever susceptibility or fatal outcomes were found after correcting for multiple hypothesis testing, although DRB1*15:03 showed the strongest, albeit non-significant, association.^[1]

Clinical Risk Assessment and Monitoring Strategies

Integrating demographic and clinical data with genetic insights can significantly enhance risk stratification and personalize medicine approaches for Lassa fever patients. Demographic analyses indicated that women and girls are significantly overrepresented among Lassa fever cases in Nigeria, suggesting increased susceptibility or exposure in this population.^[1]Additionally, patients with Lassa virus infection were found to be generally younger than controls, and younger patients were more likely to present with symptoms such as vomiting and cough.^[1] While a trend towards higher fatality in older patients was observed, it did not reach statistical significance.^[1] These clinical observations, when combined with genetic markers like those in GRM7 and LIF, could refine risk assessment models. For instance, individuals carrying high-risk genetic variants, particularly within vulnerable demographic groups, could be prioritized for early and aggressive monitoring and treatment initiation. This integrated approach allows for the identification of high-risk individuals who may benefit most from intensive care, early antiviral therapy, or other supportive measures, thereby improving monitoring strategies and potentially altering long-term implications for patient care by preventing severe complications.

Pathophysiological Insights and Therapeutic Implications

The identified genetic associations offer valuable insights into the pathophysiology of Lassa fever and suggest potential avenues for therapeutic development. TheLIFgene, associated with fatal outcomes, encodes an interleukin 6 family cytokine known to play a role in immune responses and inflammation. Previous studies have shownLIFto protect against lung injury in respiratory syncytial virus models and to be upregulated in acute HIV infection and meningococcemia.^[12]Altered regulation of this pleiotropic cytokine due to host genetic variation could profoundly impact Lassa fever severity, suggestingLIFas a potential target for immunomodulatory therapies aimed at mitigating disease progression.^[1] Similarly, the GRM7 gene, also linked to fatal outcomes, may be involved in viral entry or immune activation, with some research indicating its role in anaphylaxis models.^[13] Intriguingly, GRM7also plays an important role in the maintenance of hearing by inner-ear hair cells, which is highly relevant given that hearing loss is a notable complication of Lassa fever.^[1] Understanding the precise mechanisms by which these genes influence viral pathogenesis and host response could lead to the development of targeted treatments or preventative strategies. The discovery of a protective haplotype near LARGE1, a critical entry factor for LASV, further highlights the potential for developing therapeutics that block viral entry, representing a personalized medicine approach to prevention or early intervention based on an individual’s genetic profile.^[1]

Frequently Asked Questions About Lassa Fever

These questions address the most important and specific aspects of lassa fever based on current genetic research.

---

1. If my neighbor got really sick, will I get it badly too?

Not necessarily. Your body’s genetic makeup can significantly influence how severely you react to the virus. Some people have genetic variations near genes like GRM7 and LIF that are linked to more severe or fatal outcomes, while others might carry protective variations, such as a specific haplotype near the LARGE1 gene, which can decrease your risk of severe illness.

2. If my family gets sick often, am I more at risk?

Yes, there’s evidence that your family’s genetic background can play a role. Human genetic variation influences both how easily you might get infected and how severe the disease could be. If your family shares certain genetic predispositions, you might have similar risks for Lassa fever.

3. Does being from West Africa change my risk?

Yes, your ancestry and where you live in West Africa can matter. Genetic diversity is high in African populations, and specific genetic variants associated with Lassa fever risk or protection might be more common in certain regions or ethnic groups. This means findings about genetic associations from one area may not apply everywhere.

4. Can I know if I’m naturally resistant to Lassa fever?

Currently, there isn’t a widely available DNA test to tell you if you’re naturally resistant. However, research is identifying specific genetic variations, like certain haplotypes in the LARGE1gene, that are associated with a decreased risk of Lassa fever. As science advances, personalized risk assessment might become possible.

5. Does my immune system make a difference in how sick I get?

Absolutely. Your immune system is crucial. Researchers are investigating how variations in the human leukocyte antigen (HLA) region, which plays a key role in how your immune system recognizes invaders, are associated with different Lassa fever outcomes. These genetic differences can influence how effectively your body fights off the virus.

6. Why do some people die from Lassa fever but others recover?

The outcome is often influenced by individual genetic factors. Studies have found specific genetic variants near genes like GRM7 and LIFthat are strongly associated with fatal outcomes. These genetic differences can affect your body’s response to the infection, making some individuals more vulnerable to severe or deadly disease.

7. If I’m exposed to the virus, will I definitely get sick?

No, not everyone exposed gets sick, and many have mild or no symptoms. Your genetic makeup plays a significant role in susceptibility. For instance, the expression level of the LARGE1 gene, which modifies the virus’s entry receptor alpha-dystroglycan, can influence how easily the virus infects your cells.

8. Does what I eat or touch at home make me more vulnerable?

While diet isn’t directly linked to genetic vulnerability, contact with contaminated food or household items is the primary way Lassa virus spreads. If you are genetically predisposed to a more severe outcome, avoiding these exposures is even more critical, as your genetics could make a mild infection turn serious.

9. Why is Lassa fever so hard for doctors to diagnose correctly?

Diagnosing Lassa fever is challenging because symptoms can vary widely, and there aren’t many US FDA-approved tests available. Genetic variations among individuals can also lead to different clinical presentations, making it harder to recognize, especially in cases where people are only mildly ill or have unusual symptoms.

10. If a new treatment works for my friend, will it work for me?

It depends. While treatments aim to help everyone, individual genetic differences can affect how well you respond. The genetic landscape in West Africa is very diverse, meaning that what works effectively for one person or population might need adjustments for another due to underlying genetic variations influencing disease progression or drug metabolism.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Kotliar D et al. Genome-wide association study identifies human genetic variants associated with fatal outcome from Lassa fever. Nat Microbiol. 2024 Mar;9(3):751-762.

[2] Kunz, S. et al. “Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding.” J. Virol., vol. 79, 2005, pp. 14282–14296.

[3] Cummins, D. et al. “Acute sensorineural deafness in Lassa fever.”JAMA, vol. 264, 1990, pp. 2093–2096.

[4] Raabe, V. & Koehler, J. Laboratory diagnosis of Lassa fever. J. Clin. Microbiol. 55, 1629–1637 (2017).

[5] Bowen, M. D. et al. “Genetic diversity among Lassa virus strains.” J. Virol., vol. 74, no. 15, 2000, pp. 6992-7004.

[6] McCormick, J. B. et al. “A prospective study of the epidemiology and ecology of Lassa fever.”Journal of Infectious Diseases, vol. 155, 1987, pp. 437–444.

[7] Jae, L. T. et al. “Deciphering the glycosylome of dystroglycanopathies using haploid screens for Lassa virus entry.” Science, vol. 340, 2013, pp. 479–483.

[8] Sabeti, P. C. et al. “Genome-wide detection and characterization of positive selection in human populations.” Nature, vol. 449, 2007, pp. 913–918.

[9] Ackerman, H. et al. “A comparison of case–control and family-based association methods: the example of sickle-cell and malaria.” Annals of Human Genetics, vol. 69, 2005, pp. 559–565.

[10] Tian, C. et al. “Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections.” Nature Communications, vol. 8, 2017, p. 599.

[11] McCormick, J. B., and S. P. Fisher-Hoch. “Lassa fever.”Current Topics in Microbiology and Immunology, vol. 262, 2002, pp. 75–109.

[12] Lei, Y. et al. “LIF protects against respiratory syncytial virus-induced acute lung injury in mice.” J. Immunol, vol. 183, 2009, pp. 7551–7558.

[13] Kishi, H. et al. “Deficiency in metabotropic glutamate receptor 7 causes anaphylaxis in mice.”J. Immunol., vol. 196, 2016, pp. 508–517.